Xenon Pharmaceuticals Inc. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. This is an annual report, not a standalone fourth-quarter filing; the filing also provides unaudited Q4 results. Amounts below are U.S. dollars unless stated otherwise.
Business context
Xenon is a clinical-stage biopharmaceutical company using its “Extreme Genetics” platform to identify drug targets through rare inherited conditions. It intends to develop selected orphan and niche products itself and partner larger-market programs. Its revenue largely comes from collaboration agreements, not product sales. Glybera, licensed to uniQure, was approved in the EU; Xenon had not generated meaningful royalties from product sales by year-end.
Key programs included Teva-partnered TV-45070 for pain, with a Phase 2b knee osteoarthritis trial underway; Genentech-partnered GDC-0276, which entered Phase 1 in September 2014; and proprietary preclinical programs for Dravet syndrome and acne candidate XEN801.
Financial results and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $28.370 million | $27.356 million |
| Operating expenses | $17.264 million | $17.644 million |
| Operating income | $11.106 million | $9.712 million |
| Net income | $13.018 million | $12.032 million |
| Operating cash flow | $0.266 million | $(3.322) million |
| Cash, cash equivalents and marketable securities at year-end | $84.041 million | $49.276 million |
| Working capital at year-end | $70.656 million | $31.666 million |
| Notes payable at year-end | None | None |
Revenue increased about 3.7% year over year. Operating expenses declined about 2.2%; operating margin was approximately 39%. Net income included a $1.344 million foreign-exchange gain and $0.568 million in interest income. Revenue was principally collaboration revenue ($28.366 million); royalties were just $4,000. The company reported an accumulated deficit of $103.734 million despite profits in 2013 and 2014.
Cash from operations was modest despite reported net income, reflecting, among other factors, a $14.410 million reduction in deferred revenue. Investing activities used $3.244 million, while financing activities provided $41.124 million, principally in connection with the November 2014 IPO and concurrent private placement. The company reported no outstanding debt.
For Q4 2014, revenue was $4.878 million, operating income was $35,000, and net income attributable to common shareholders was $1.224 million. The quarterly table reports basic and diluted earnings per share of $0.14 and $0.13, respectively.
Changes, outlook and key risks
- Net income was $13.018 million versus $12.032 million in 2013, but the company cautioned that it did not expect sustained profitability. Reported 2013 common-shareholder income and per-share figures were affected by the preferred-share allocation; preferred shares converted to common shares in connection with the IPO.
- Genentech milestone revenue included $8.0 million recognized in 2014 after Health Canada approved the GDC-0276 clinical trial application. The filing recognizes the Teva and Genentech upfront payments over performance periods, so reported collaboration revenue is not equivalent to cash received in the year.
- The November IPO raised approximately $34.2 million net of offering costs; a concurrent private placement to a Roche affiliate raised $4.455 million before offering costs. Preferred-share conversion and new share issuance materially changed the capital structure.
- Management estimated existing cash, marketable securities and expected collaboration research funding would cover operating and capital needs for at least 12–24 months from the report date. It also said further capital would likely be needed; estimates depend on development costs, trial progress and collaboration payments.
- Management expected higher research and development spending as programs advanced, alongside greater public-company and general and administrative costs. The company had no product sales revenue and relied on collaborators for development, milestone payments and commercialization.
- Near-term program expectations included Teva’s knee osteoarthritis Phase 2b data in Q3 2015 and planned PHN trial enrollment beginning in March 2015; Genentech expected GDC-0276 Phase 1 enrollment to complete in the second half of 2015. Xenon anticipated filing an IND or equivalent for XEN801 in Q2 2015 and an IND for its Dravet program in 2016. These were expectations, not guarantees.
- Principal risks include clinical and regulatory failure, uncertain partner priorities and milestone timing, limited commercialization experience, dependence on third-party manufacturing, intellectual-property challenges, future financing and dilution, and uncertain coverage and reimbursement. TV-45070’s earlier pain studies included small exploratory trials; some primary endpoints did not reach statistical significance.
- Foreign exchange was a material source of earnings variability. The Canadian dollar was the functional currency through 2014; Xenon changed to the U.S. dollar functional currency on January 1, 2015. Management reported disclosure controls were effective, but the filing did not include management’s assessment or auditor attestation of internal control over financial reporting because of the new-public-company transition period.
Investor facts to verify
- Whether the projected 12–24-month cash runway remains adequate after actual spending, trial costs and collaboration funding; and whether additional financing is required.
- Whether Teva’s osteoarthritis and PHN trials meet timelines and produce clinically meaningful results, and how Genentech’s Phase 1 program progresses.
- Whether Glybera launched as planned and generates sales, royalties or sublicense-related payments for Xenon.
- How much of future revenue depends on milestone events versus recurring research funding, and whether reported revenue converts into operating cash.
- The effects of the functional-currency change, Canadian-dollar exposure and potential share issuance or option dilution on reported results and per-share value.
- Progress on XEN801 and Dravet IND plans, and the company’s readiness to assess and report internal-control effectiveness as a public company.